Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study Data from 47,768 cancer survivors and ...

Researchers at the Federal University of São Carlos (UFSCar) in the state of São Paulo, Brazil, in partnership with colleagues at University College London in the UK have discovered an efficient, ...